Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5458514 in mCRPC
NCT06990880Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2025
- Primary completion
- Oct 2027
- Modality
- T-cell Engagers
- Countries
- 5
01
Overview
A Phase 2 trial of GSK5458514 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by GSK. Started Jun 2025; status: recruiting.
02
Drugs
GSK5458514
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06990880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990880.